Cargando…
Can Target-to-Background Ratio Measurement Lead to Detection and Accurate Quantification of Atherosclerosis With FDG PET? Likely Not
The introduction of FDG in 1976 started a new discipline and enhanced the role of molecular imaging in medicine. While the initial intent with this tracer was to determine brain function in a variety of neuropsychiatric disorders, over time, this powerful approach has made a major impact on managing...
Autores principales: | Alavi, Abass, Werner, Thomas J., Høilund-Carlsen, Poul Flemming., Revheim, Mona-Elisabeth |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9071036/ https://www.ncbi.nlm.nih.gov/pubmed/35384906 http://dx.doi.org/10.1097/RLU.0000000000004131 |
Ejemplares similares
-
FDG PET (and MRI) for Monitoring Immunotherapy in Alzheimer Disease
por: Høilund-Carlsen, Poul F., et al.
Publicado: (2023) -
Aducanumab-Related Amyloid-Related Imaging Abnormalities: Paean or Lament?
por: Høilund-Carlsen, Poul F., et al.
Publicado: (2022) -
NaF-PET Imaging of Atherosclerosis Burden
por: Høilund-Carlsen, Poul F., et al.
Publicado: (2023) -
Alzheimer’s Disease at a Crossroad: Time to Part from Amyloid to More Promising Aspects—Atherosclerosis for a Start
por: Høilund-Carlsen, Poul F., et al.
Publicado: (2022) -
Atherosclerosis Burdens in Diabetes Mellitus: Assessment by PET Imaging
por: Høilund-Carlsen, Poul F., et al.
Publicado: (2022)